> Details

Boeddinghaus, Jasper; Twerenbold, Raphael; Nestelberger, Thomas; Koechlin, Luca; Wussler, Desiree; Meier, Mario; Troester, Valentina; Zimmermann, Tobias; Badertscher, Patrick; Wildi, Karin; Rubini Giménez, Maria; Lopez-Ayala, Pedro; Potlukova, Eliska; Miró, Òscar; Martin-Sanchez, F Javier; Kawecki, Damian; Geigy, Nicolas; Keller, Dagmar I; Reichlin, Tobias; Mueller, Christian; du Fay de Lavallaz, Jeanne; Walter, Joan Elias; Freese, Michael; Puelacher, Christian; [...]

Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Clinical Use of a New High-Sensitivity Cardiac Troponin I Assay in Patients with Suspected Myocardial Infarction
  • Contributor: Boeddinghaus, Jasper; Twerenbold, Raphael; Nestelberger, Thomas; Koechlin, Luca; Wussler, Desiree; Meier, Mario; Troester, Valentina; Zimmermann, Tobias; Badertscher, Patrick; Wildi, Karin; Rubini Giménez, Maria; Lopez-Ayala, Pedro; Potlukova, Eliska; Miró, Òscar; Martin-Sanchez, F Javier; Kawecki, Damian; Geigy, Nicolas; Keller, Dagmar I; Reichlin, Tobias; Mueller, Christian; du Fay de Lavallaz, Jeanne; Walter, Joan Elias; Freese, Michael; Puelacher, Christian; [...]
  • Published: Oxford University Press (OUP), 2019
  • Published in: Clinical Chemistry, 65 (2019) 11, Seite 1426-1436
  • Language: English
  • DOI: 10.1373/clinchem.2019.304725
  • ISSN: 1530-8561; 0009-9147
  • Origination:
  • Footnote:
  • Description: Abstract BACKGROUND We aimed to validate the clinical performance of the high-sensitivity cardiac troponin I [VITROS® Immunodiagnostic Products hs Troponin I (hs-cTnI-VITROS)] assay. METHODS We enrolled patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by 2 independent cardiologists considering all clinical information, including cardiac imaging: first, using serial hs-cTnT-Elecsys (primary analysis) and, second, using hs-cTnI-Architect (secondary analysis) measurements in addition to the clinically used (hs)-cTn. hs-cTnI-VITROS was measured at presentation and at 1 h in a blinded fashion. The primary objective was direct comparison of diagnostic accuracy as quantified by the area under the ROC curve (AUC) of hs-cTnI-VITROS vs hs-cTnT-Elecsys and hs-cTnI-Architect, and in a subgroup also hs-cTnI-Centaur and hs-cTnI-Access. Secondary objectives included the derivation and validation of an hs-cTnI-VITROS-0/1-h algorithm. RESULTS AMI was the adjudicated final diagnosis in 158 of 1231 (13%) patients. At presentation, the AUC for hs-cTnI-VITROS was 0.95 (95% CI, 0.93–0.96); for hs-cTnT-Elecsys, 0.94 (95% CI, 0.92–0.95); and for hs-cTnI-Architect, 0.92 (95% CI, 0.90–0.94). AUCs for hs-cTnI-Centaur and hs-cTnI-Access were 0.95 (95% CI, 0.94–0.97). Applying the derived hs-cTnI-VITROS-0/1-h algorithm (derivation cohort n = 519) to the validation cohort (n = 520), 53% of patients were ruled out [sensitivity, 100% (95% CI, 94.1–100)] and 14% of patients were ruled in [specificity, 95.6% (95% CI, 93.4–97.2)]. Patients ruled out by the 0/1-h algorithm had a survival rate of 99.8% at 30 days. Findings were confirmed in the secondary analyses using the adjudication including serial measurements of hs-cTnI-Architect. CONCLUSIONS The hs-cTnI-VITROS assay has at least comparable diagnostic accuracy with the currently best validated hs-cTnT and hs-cTnI assays. ClinicalTrials.gov Identifier NCT00470587.